000119837 001__ 119837
000119837 005__ 20240228145442.0
000119837 0247_ $$2doi$$a10.1158/1078-0432.CCR-16-0860
000119837 0247_ $$2pmid$$apmid:27535980
000119837 0247_ $$2ISSN$$a1078-0432
000119837 0247_ $$2ISSN$$a1557-3265
000119837 0247_ $$2altmetric$$aaltmetric:10680626
000119837 037__ $$aDKFZ-2017-00432
000119837 041__ $$aeng
000119837 082__ $$a610
000119837 1001_ $$0P:(DE-He78)97208bef945f0ab6bf33ed9925685de4$$aChudasama, Priya$$b0$$eFirst author
000119837 245__ $$aTargeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
000119837 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2017
000119837 3367_ $$2DRIVER$$aarticle
000119837 3367_ $$2DataCite$$aOutput Types/Journal article
000119837 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1533718857_21515
000119837 3367_ $$2BibTeX$$aARTICLE
000119837 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119837 3367_ $$00$$2EndNote$$aJournal Article
000119837 520__ $$aPurpose: Altered FGFR1 signaling has emerged as a therapeutic target in epithelial malignancies. In contrast, the role of FGFR1 in soft-tissue sarcoma (STS) has not been established. Prompted by the detection and subsequent therapeutic inhibition of amplified FGFR1 in a patient with metastatic leiomyosarcoma, we investigated the oncogenic properties of FGFR1 and its potential as a drug target in patients with STS.Experimental Design: The frequency of FGFR1 amplification and overexpression, as assessed by FISH, microarray-based comparative genomic hybridization and mRNA expression profiling, SNP array profiling, and RNA sequencing, was determined in three patient cohorts. The sensitivity of STS cell lines with or without FGFR1 alterations to genetic and pharmacologic FGFR1 inhibition and the signaling pathways engaged by FGFR1 were investigated using viability assays, colony formation assays, and biochemical analysis.Results: Increased FGFR1 copy number was detected in 74 of 190 (38.9%; cohort 1), 13 of 79 (16.5%; cohort 2), and 80 of 254 (31.5%; cohort 3) patients. FGFR1 overexpression occurred in 16 of 79 (20.2%, cohort 2) and 39 of 254 (15.4%; cohort 3) patients. Targeting of FGFR1 by RNA interference and small-molecule inhibitors (PD173074, AZD4547, BGJ398) revealed that the requirement for FGFR1 signaling in STS cells is dictated by FGFR1 expression levels, and identified the MAPK-ERK1/2 axis as critical FGFR1 effector pathway.Conclusions: These data identify FGFR1 as a driver gene in multiple STS subtypes and support FGFR1 inhibition, guided by patient selection according to the FGFR1 expression and monitoring of MAPK-ERK1/2 signaling, as a therapeutic option in this challenging group of diseases. Clin Cancer Res; 23(4); 962-73. ©2016 AACR.
000119837 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000119837 588__ $$aDataset connected to CrossRef, PubMed,
000119837 7001_ $$aRenner, Marcus$$b1
000119837 7001_ $$aStraub, Melanie$$b2
000119837 7001_ $$0P:(DE-HGF)0$$aMughal, Sadaf S$$b3
000119837 7001_ $$0P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0$$aHutter, Barbara$$b4
000119837 7001_ $$0P:(DE-He78)ed2ebe0562004383b2ecc486d1ad6932$$aKosaloglu-Yalcin, Zeynep$$b5
000119837 7001_ $$0P:(DE-He78)02ca10f1a87831f3557ee5ad6ce55b52$$aSchweßinger, Ron$$b6
000119837 7001_ $$aScheffler, Matthias$$b7
000119837 7001_ $$aAlldinger, Ingo$$b8
000119837 7001_ $$aSchimmack, Simon$$b9
000119837 7001_ $$aPersigehl, Thorsten$$b10
000119837 7001_ $$aKobe, Carsten$$b11
000119837 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b12
000119837 7001_ $$0P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de$$avon Kalle, Christof$$b13
000119837 7001_ $$aSchirmacher, Peter$$b14
000119837 7001_ $$0P:(DE-He78)525e4a71a438bb8752e2f2ed4718a811$$aBeckhaus, Marie-Kristin$$b15$$udkfz
000119837 7001_ $$0P:(DE-He78)1efb774993effe7a66a6ffc1b1cf9ccb$$aWolf, Stephan$$b16
000119837 7001_ $$aHeining, Christoph$$b17
000119837 7001_ $$0P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aGröschel, Stefan$$b18
000119837 7001_ $$aWolf, Jürgen$$b19
000119837 7001_ $$0P:(DE-He78)fc949170377b58098e46141d95c72661$$aBrors, Benedikt$$b20
000119837 7001_ $$aWeichert, Wilko$$b21
000119837 7001_ $$0P:(DE-He78)157277fe62f07df1732f9d126a51d1b9$$aGlimm, Hanno$$b22
000119837 7001_ $$0P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250$$aScholl, Claudia$$b23
000119837 7001_ $$aMechtersheimer, Gunhild$$b24
000119837 7001_ $$aSpecht, Katja$$b25
000119837 7001_ $$0P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aFröhling, Stefan$$b26$$eLast author
000119837 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-16-0860$$gVol. 23, no. 4, p. 962 - 973$$n4$$p962 - 973$$tClinical cancer research$$v23$$x1557-3265$$y2017
000119837 909CO $$ooai:inrepo02.dkfz.de:119837$$pVDB
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)97208bef945f0ab6bf33ed9925685de4$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed2ebe0562004383b2ecc486d1ad6932$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)02ca10f1a87831f3557ee5ad6ce55b52$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)525e4a71a438bb8752e2f2ed4718a811$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1efb774993effe7a66a6ffc1b1cf9ccb$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fc949170377b58098e46141d95c72661$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)157277fe62f07df1732f9d126a51d1b9$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000119837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000119837 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000119837 9141_ $$y2017
000119837 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2015
000119837 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119837 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119837 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119837 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119837 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119837 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119837 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119837 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000119837 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119837 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN CANCER RES : 2015
000119837 9201_ $$0I:(DE-He78)G100-20160331$$kG100$$lTranslationale Onkologie$$x0
000119837 9201_ $$0I:(DE-He78)G200-20160331$$kG200$$lAngewandte Bioinformatik$$x1
000119837 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x2
000119837 9201_ $$0I:(DE-He78)G010-20160331$$kG010$$lGeschäftsstelle$$x3
000119837 9201_ $$0I:(DE-He78)W190-20160331$$kW190$$lHochdurchsatz-Sequenzierung$$x4
000119837 9201_ $$0I:(DE-He78)G102-20160331$$kG102$$lAngewandte Funktionelle Genomik$$x5
000119837 9201_ $$0I:(DE-He78)G240-20160331$$kG240$$lMolekulare Leukämogenese$$x6
000119837 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x7
000119837 9201_ $$0I:(DE-He78)L701-20160331$$kL701$$lDKTK München$$x8
000119837 980__ $$ajournal
000119837 980__ $$aVDB
000119837 980__ $$aI:(DE-He78)G100-20160331
000119837 980__ $$aI:(DE-He78)G200-20160331
000119837 980__ $$aI:(DE-He78)D120-20160331
000119837 980__ $$aI:(DE-He78)G010-20160331
000119837 980__ $$aI:(DE-He78)W190-20160331
000119837 980__ $$aI:(DE-He78)G102-20160331
000119837 980__ $$aI:(DE-He78)G240-20160331
000119837 980__ $$aI:(DE-He78)L101-20160331
000119837 980__ $$aI:(DE-He78)L701-20160331
000119837 980__ $$aUNRESTRICTED